Analysis of global COVID-19 vaccine policies with public value mapping approach

Abstract

The public value theory argues that a social benefit should occur as a result of the policies, actions and operations of public administrations. However, the production of social benefit is possible by bringing together various and different actors, factors and interests in a certain harmony. For this reason, it is important to determine whether a value is formed as a result of all policies, actions and operations of public administrations. The “public value failure model” and the “public value mapping approach” included in the model were also created for this purpose. As a policy analysis method, the public value mapping approach allows to determine whether public value is formed within the framework of certain criteria. The biggest problem of the global community in the current period is the COVID-19 pandemic. Governments and international organizations are implementing various policies to combat the COVID-19 and its negative consequences. Vaccine studies are the most important part of these policies. In this study, global vaccine policies were tried to be analysed using the public value mapping approach. As a result of the analysis, it was concluded that there is injustice and inequality on a global scale in terms of access to and vaccination, and therefore, public value cannot be created in the current situation.

Keywords

• public value
• public value failure
• public value mapping
• public policies
• COVID-19

Küresel COVID-19 aşı politikalarının kamu değeri haritalama yaklaşımı ile analizi

Abstract

Kamu değer teorisi, kamu yönetimlerinin ürettikleri politikaların, eylem ve işlemlerinin sonucunda toplumsal bir faydanın oluşması gerektiğini ileri sürmektedir. Ancak toplumsal faydanın üretilmesi, çok çeşitli ve farklı aktör, etken ve çıkarın belirli bir uyum içerisinde bir araya getirilmesi ile mümkün olmaktadır. Bu nedenle kamu yönetimlerinin tüm politika, eylem ve işlemleri sonucunda bir değerin oluşup oluşmadığının belirlenmesi önem arz etmektedir. “Kamu değer başarısızlığı modeli” ve model içerisinde yer alan “kamu değeri haritalama yaklaşımı” da bu amaçla oluşturulmuştur. Bir politika analiz yöntemi olarak kamu değeri haritalama yaklaşımı, belirli kriterler çerçevesinde kamu değerinin oluşup oluşmadığını tespit etmeye olanak sağlamaktadır. İçinde bulunduğumuz dönemde küresel toplumun en büyük sorunu COVID-19 pandemisidir. Hükümetler ve uluslararası kuruluşlar COVID-19 ve olumsuz sonuçlarıyla mücadelede çeşitli politikalar uygulamaktadır. Aşı çalışmaları bu politikaların en önemli kısmını oluşturmaktadır. Bu çalışmada kamu değeri haritalama yaklaşımı kullanılarak küresel aşı politikaları analiz edilmeye çalışılmıştır. Analiz sonucunda aşıya erişim ve aşılanma konularında küresel ölçekte adaletsizlik ve eşitsizliğin bulunduğu, dolayısıyla mevcut durumda kamu değerinin oluşturulamadığı sonucuna ulaşılmıştır.

Keywords

• kamu değeri
• kamu değer başarısızlığı
• kamu değeri haritalama
• kamu politikaları
• COVID-19

References

1. Alford, J., Douglas, S., Geuijen, K. ve Hart, P. (2017). Ventures in public value management: Introduction to the symposium. Public Management Review, 19(5), 589-604. http://dx.doi.org/10.1080/14719037.2016.1192160
2. Ashraf, B. N. (2020). Economic impact of government interventions during the COVID-19 pandemic: International evidence from financial markets. Journal of Behavioral and Experimental Finance, 27, 1-9. http://dx.doi.org/10.1016/j.jbef.2020.100371
3. Beck Jørgensen, T. ve Bozeman, B. (2007). Public values an inventory. Administration & Society, 39(3), 354-381. http://dx.doi.org/10.1177/0095399707300703
4. Blaug, R., Horner, L. ve Lekhi, R. (2006). Public value, politics and public management. The Work Foundation.
5. Bozeman, B. (2002). Public-value failure: When efficient markets may not do. Public Administration Review, 62(2), 145-161. http://dx.doi.org/10.1111/0033-3352.00165
6. Bozeman, B. (2003). Public value mapping of science outcomes: Theory and method. A Monograph of the Public Value Mapping Project of the Center for Science, Policy and Outcomes. Columbia University.
7. Bozeman, B. (2009). Public values theory: Three big questions. International Journal of Public Policy, 4(5), 369- 375. http://dx.doi.org/10.1504/IJPP.2009.025077
8. Bozeman, B. (2018). Public values: citizens’ perspective. Public Management Review, 1-24. http://dx.doi.org/10.1080/14719037.2018.1529878

9. Bozeman, B. ve Johnson, J. (2015). The political economy of public values: A case for the public sphere and progressive opportunity. American Review of Public Administration, 45(1), 61-85. http://dx.doi.org/10.1177/0275074014532826
10. Bozeman, B. ve Sarawitz, D. (2011). Public value mapping and science policy evaluation. Minerva, 49, 1-23. http://dx.doi.org/10.1007/s11024-011-9161-7
11. Bracci, E., Gagliardo, E. D. ve Bigoni, M. (2014). Performance management systems and public value strategy: A case study. Public value management, Measurement and Reporting, 3, 129-157. http://dx.doi.org/10.1108/S2051-663020140000003006
12. Brodeur, A., Islam, A., Gray, D. ve Bhuiyan, S. J. (2020). A literature review of the economics of COVID-19. IZA Discussion Papers, IZA DP No. 13411. IZA Institute of Labor Economics. 05 Mayıs 2021 tarihinde https://ssrn.com/abstract=3636640 adresinden erişildi.
13. Brüssow, H. (2020). Efforts towards a COVID-19 vaccine. Environmental Microbiology, 22(10), 4071-4084. http://dx.doi.org/10.1111/1462-2920.15225
14. Bryson, J. M., Crosby, B. C. ve Bloomberg, L. (2014). Public value governance: Moving beyond traditional public administration and the new public management. Public Administration Review, 74(4), 445-456. http://dx.doi.org/10.1111/puar.12238
15. Bryson, J. M., Crosby, B. C. ve Bloomberg, L. (2015). Introduction. J. M. Bryson, B. C. Crosby ve L. Bloomberg (Ed.), Creating public value in practice içinde (ss. 4-29). CRC Press.
16. Case, K. E., Fair, R. C. ve Oster, S. M. (2012). Principles of economics. Prentice Hall.
17. Center for Global Development. (2021). Would exempting COVID-19 vaccines from intellectual property rights improve global access and equity? 05 Mayıs 2021 tarihinde https://www.cgdev.org/debate/would-exempting- covid-19-vaccines-intellectual-property-rights-improve-global-access adresinden erişildi.
18. Cheng, C., Barceló, J., Hartnett, A. S., Kubinec, R. ve Messerschmidt, L. (2020). COVID-19 government response event dataset (CoronaNet v.1.0). Nature Human Behaviour, 4, 756-768. http://dx.doi.org/10.1038/s41562-020-09097
19. Cheval, S., Adamescu, C. M., Georgiadis, T., Herrnegger, M., Piticar, A. ve Legates, D. R. (2020). Observed and potential impacts of the COVID-19 pandemic on the environment. Int. J. Environ. Res. Public Health, 17, 1-25. http://dx.doi.org/10.3390/ijerph17114140
20. Council of Europe. (2021). Public debate. 19 Mayıs 2021 tarihinde https://www.coe.int/en/web/bioethics/public-debate adresinden erişildi.
21. Ćwiklicki, M. (2016). Comparison of public value measurement frameworks. Zarządzanie Publiczne, 1(35), 20-31. http://dx.doi.org/10.15678/ZP.2016.35.1.02
22. De Vries, M. S. ve Kim, P. S. (2011). Introduction to value and virtue in public administration. M. S. De Vries ve P. S. Kim (Ed.), Value and Virtue in Public Administration:A Comparative Perspective içinde (ss. 1-17). Palgrave Macmillan.
23. Deloitte. (2020). Addressing the impact of COVID-19: Crisis management and resilience planning. 19 Mayıs 2021 tarihinde https://www2.deloitte.com/ch/en/pages/risk/articles/covid-19-institute-crisis-and-resilience-planning.html adresinden erişildi.
24. Deutsche Welle. (2021a, March 21). Coronavirus: EU 'not ready' to share COVID vaccines with poorer countries. https://www.dw.com/en/coronavirus-eu-not-ready-to-share-covid-vaccines-with-poorer-countries/a-56944274.
25. Deutsche Welle. (2021b, April 12). Vaccine inequities are hindering COVID-19 response. https://www.dw.com/en/vaccine-inequities-are-hindering-covid-19-response/a-57166872
26. Dyer, O. (2021). Covid-19: Countries are learning what others paid for vaccines. The BMJ, 372:n281. http://dx.doi.org/10.1136/bmj.n281
27. Elavarasan, R. M. ve Pugazhendhi, R. (2020). Restructured society and environment: A review on potential technological strategies to control the COVID-19 pandemic. Science of the Total Environment (725), 1-18. http://dx.doi.org/10.1016/j.scitotenv.2020.138858
28. Euronews. (2021, March 22). Global COVID vaccine inequality 'becoming more grotesque every day,' WHO warns. https://www.euronews.com/2021/03/22/global-covid-vaccine-inequality- becoming-more-grotesque-every-day-who-warns
29. Feeney, M. K. ve Bozeman, B. (2007). Public values and public failure: Implications of the 2004-2005 flu vaccine case. Public Integrity, 9(2), 175-190. http://dx.doi.org/10.2753/PIN1099-9922090204
30. Forman, R., Shah, S., Jeurissen, P., Jit, M. ve Mossialos, E. (2021). COVID-19 vaccine challenges: What have we learned so far and what remains to be done? Health Policy, (125), 553-567. http://dx.doi.org/10.1016/j.healthpol.2021.03.013
31. Fukumoto, E. ve Bozeman, B. (2019). Public values theory: What is missing? American Review of Public Administration, 49(6), 635-648. http://dx.doi.org/10.1177/0275074018814244
32. Garofalo, C. (2011). Governance and values in contemporary public service. M. S. De Vries ve P. S. Kim (Ed.), Value and Virtue in Public administration: A comparative perspective içinde (ss. 17-33). Palgrave Macmillan.
33. Gates, B. (2020). Responding to COVID-19-A once-in-a-century pandemic? The New England Journal of Medicine, 382(18), 1677-1679. http://dx.doi.org/10.1056/NEJMp2003762
34. Gavi The Vaccine Alliance. (2021). Responding to COVID-19. 19 Mayıs 2021 tarihinde https://www.gavi.org/covid19 adresinden erişildi.
35. Goodell, J. W. (2020). COVID-19 and finance: Agendas for future research. Finance Research Letters, 35, 1-5. http://dx.doi.org/10.1016/j.frl.2020.101512
36. Haleem, A., Javaid, M. ve Vaishya, R. (2020). Effects of COVID-19 pandemic in daily life. Current Medicine Research and Practice, (10), 78-79. http://dx.doi.org/10.1016/j.cmrp.2020.03.011
37. Haug, N., Geyrhofer, L., Londei, A., Dervic, E., Desvars-Larrive, A., Loreto, V. vd. (2020). Ranking the effectiveness of worldwide COVID-19 government interventions. Nature Human Behaviour, 4, 1303- 1312. http://dx.doi.org/10.1038/s41562-020-01009-0
38. He, H. ve Harris, L. (2020). The impact of COVID-19 pandemic on corporate social responsibility and marketing philosophy. Journal of Business Research, (116), 176-182. http://dx.doi.org/10.1016/j.jbusres.2020.05.030
39. Hopman, J., Allegranzi, B. ve Mehtar, S. (2020). Managing COVID-19 in low- and middle-income countries. JAMA, 323(16), 1549-1550. http://dx.doi.org/10.1001/jama.2020.4169
40. Hsiang, S., Allen, D., Annan-Phan, S., Bell, K., Bolliger, I., Chong, T. vd. (2020). The effect of large- scale anti-contagion policies on the COVID-19 pandemic. Nature, 584, 262-266. http://dx.doi.org/10.1038/s41586-020-2404-8
41. ILO-OECD. (2020). The impact of the COVID-19 pandemic on jobs and incomes in G20 economies. ILO-OECD paper prepared at the request of G20 Leaders Saudi Arabia’s G20 Presidency 2020. 05 Mayıs 2021 tarihinde https://www.ilo.org/wcmsp5/groups/public/---dgreports/---cabinet/documents/publication/wcms_756331.pdf adresinden alındı.
42. Imran, A. ve Alharbi, O. M. (2020). COVID-19: Disease, management, treatment, and social impact. Science of the Total Environment, (728), 1-6. http://dx.doi.org/10.1016/j.scitotenv.2020.138861
43. International Observatory Human Rights. (2021, April 06). Covid-19 vaccine distribution highlights social inequality. https://observatoryihr.org/news/covid-19-vaccine-distribution-highlights- social-inequality/
44. Iserson, K. V. (2021). SARS-CoV-2 (COVID-19) Vaccine development and production: An ethical way forward. Cambridge Quarterly of Healthcare Ethics, (30), 59-68. http://dx.doi.org/10.1017/S096318012000047X
45. Katz, I. Y., Weintraub, R., Bekker, L. G. ve Brandt, A. M. (2021). From vaccine nationalism to vaccine equity — Finding a path forward. The New England Journal of Medicine, 384(14), 1281-1283. http://dx.doi.org/10.1056/NEJMp2103614
46. Kelly, G., Mulgan, G. ve Muers, S. (2002). Creating public value: An analytical framework for public service reform. UK: Cabinet Office Strategy Unit.
47. Kowalik, M. (2021, March 01). Discrimination on the basis of vaccination status (is inherently wrong). https://blogs.bmj.com/medical-ethics/2021/03/01/discrimination-on-the-basis-of- vaccination-status-is-inherently-wrong/
48. Laine, C., Cotton, D. Ve Moyer, D. V. (2021). COVID-19 vaccine: Promoting vaccine acceptance. Annals of International Medicine, 174(2), 252-253. http://dx.doi.org/10.7326/M20-8008
49. Lazarus, J. V., Ratzan, S. C., Palayew, A., Gostin, L. O., Larson, H. J., Rabin, K. vd. (2021). A global survey of potential acceptance of a COVID-19 vaccine. Nature Medicine, 27, 225-227. http://dx.doi.org/10.1038/s41591-020-1124-9
50. Madhav, N., Oppenheim, B., Gallivan, M., Mulembakani, P., Rubin, E. Ve Wolfe, N. (2017). Pandemics: Risks, impacts, and mitigation. disease control priorities: Improving health and reducing poverty içinde (ss. 315- 345). The International Bank for Reconstruction and Development/The World Bank. http://dx.doi.org/10.1596/978-1-4648-0527-1_ch17
51. Maliszewska, M., Mattoo, A. ve van der Mensbrugghe, D. (2020). The potential impact of COVID-19 on GDP and trade: A preliminary assessment. Policy Research Working Papper 9211. World Bank Group.
52. Moore, M. H. (1995). Creating public value: Strategic management in government. Harward University Press.
53. Nabatchi, T. (2012). Putting the “public” back in public values research: Designing participation to identify and respond to values. Public Administration Review, (72), 699-708. http://dx.doi.org/10.1111/j.1540- 6210.2012.02544.x
54. Nabatchi, T. (2018). Public values frames in administration and governance. Perspectives on Public Management and Governance, 1(1), 59-72. http://dx.doi.org/10.1093/ppmgov/gvx009
55. O’Flynn, J. (2007). From new public management to public value: Paradigmatic change and managerial implications. The Australian Journal of Public Administration, 66(3), 353-366. http://dx.doi.org/10.1111/j.1467-8500.2007.00545.x
56. OECD. (2021). Enhancing public trust in COVID-19 vaccination: The role of governments. 05 Mayıs 2021 tarihinde https://read.oecd-ilibrary.org/view/?ref=1094_1094290-a0n03doefx&title=Enhancing-public-trust-in-COVID-19-vaccination-The-role-of-governments adresinden alındı.
57. OHCR ve WHO. (2008). The Right to Health. (Fact Sheet No. 31).19 Mayıs 2021 tarihinde https://www.ohchr.org/documents/publications/factsheet31.pdf adresinden alındı.
58. O'Shea, B. (2021, May 12). Vaccine passports or discrimination liceencess? https://www.nortonrosefulbright.com/en/knowledge/publications/d55ab991/vaccine-passports-or-discrimination-licences
59. Our World in Data. (2021). Coronavirus (COVID-19) vaccinations. 01 Temmuz 2021 tarihinde https://ourworldindata.org/covid-vaccinations adresinden alındı. Pindyck, R. S. ve Rubinfeld, D. L. (2013). Microeconomics. Pearson.
60. Pyszczynski, T., Lockett, M., Greenberg, J. ve Solomon, S. (2020). Terror management theory and the COVID- 19 pandemic. Journal of Humanistic Psychology, Special Issue, 1-17. http://dx.doi.org/10.1177/0022167820959488
61. Rao, H. R., Vemprala, N., Akello, P. ve Valecha, R. (2020). Retweets of officials’ alarming vs reassuring messages during the COVID-19 pandemic: Implications for crisis management. International Journal of Information Management, (55), 1-6. http://dx.doi.org/10.1016/j.ijinfomgt.2020.102187
62. Schwartz, J. L. (2020). Evaluating and deploying COVID-19 vaccines—The importance of transparency, scientific integrity,and public trust. The New England Journal of Medicine, (383), 1703-1705. http://dx.doi.org/10.1056/NEJMp2026393
63. Singh, J. ve Singh, J. (2020). COVID-19 and its impact on society. Electronic Research Journal of Social Sciences and Humanities, 2(1), 168-172. SSRN: https://ssrn.com/abstract=3567837
64. Smith, R. F. (2004). Focusing on public value: Something New and something old. Australian Journal of Public Administration, (63), 68-79. http://dx.doi.org/10.1111/j.1467-8500.2004.00403.x
65. Stojkoski, V., Utkovski, Z., Jolakoski, P., Tevdovsk, D. ve Kocarev, L. (2020). The socio-economic determinants of the coronavirus disease (COVID-19) pandemic. http://dx.doi.org/10.1101/2020.04.15.20066068
66. Stoker, G. (2006). Public value management a new narrative for networked governance? American Review of Public Administration, 36(1), 41-57. http://dx.doi.org/10.1177/0275074005282583
67. Susi, M. ve Pajuste, T. (2021). COVID-19 “vaccine passports”: An exploratory study of 23 countries. Tallinn University. 19 Mayıs 2021 tarihinde https://gdhrnet.eu/wp-content/uploads/GDHRNet-Study-2.- Vaccine-passports.pdf adresinden alındı.
68. Turkel, E. ve Turkel, G. (2016). Public value theory: Reconciling public interests, administrative autonomy and efficiency. Review of Public Administration and Management, 4(2), 1-7. http://dx.doi.org/10.4172/2315-7844.1000189
69. UN News. (2021, January 18). WHO chief warns against ‘catastrophic moral failure’ in COVID-19 vaccine access. https://news.un.org/en/story/2021/01/1082362
70. United Nations. (2020). Impact of the COVID-19 pandemic on trade and development: Transitioning to a new normal. United Nations.
71. van Barneveld, K., Quinlan, M., Kriesler, P., Junor, A., Baum, F., Chowdhury, A. vd. (2020). The COVID-19 pandemic: Lessons on building more equal and sustainable societies. The Economic and Labour Relations Review, 31(2), 133-157. http://dx.doi.org/10.1177/1035304620927107
72. Wang, X. ve Wang, Z. (2019). Beyond efficiency or justice: The structure and measurement of public servants’ public values preferences. Administration & Society, 52(2), 1-29. https://doi.org/10.1177/0095399719843658
73. WHO Regional Office for Europe. (2013). Health 2020: A European policy framework and strategy for the 21st century. WHO Regional Office for Europe.
74. Wibawa, T. (2021). COVID-19 vaccine research and development: Ethical issues. Tropical Medicine and International Health, 26(1), 14-19. http://dx.doi.org/10.1111/tmi.13503 World Health Organization. (1946). Constitution of the World Health Organization. 19 Mayıs 2021 tarihinde https://www.who.int/governance/eb/who_constitution_en.pdf adresinden alındı.
75. World Health Organization. (2020). Accelerating a safe and effective COVID-19 vaccine. 31 Mayıs 2021 tarihinde https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/accelerating-a-safe-and-effective-covid-19-vaccine adresinden alındı.
76. World Health Organization. (2021a). Coronavirus disease (COVID-19) pandemic. 31 Mayıs 2021 tarihinde https://www.who.int/emergencies/diseases/novel-coronavirus-2019 adresinden alındı.
77. World Health Organization. (2021b). WHO Director-General's opening remarks at the media briefing on COVID-19–22 March 2021. 31 Mayıs 2021 tarihinde https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-22-march-2021 adresinden alındı.
78. World Health Organization. (2021c). WHO Coronavirus (COVID-19) Dashboard. 01 Temmuz 2021 tarihinde https://covid19.who.int/ adresinden alındı.
79. World Health Organization. (2021d). Draft landscape and tracker of COVID-19 candidate vaccines. 01 Temmuz 2021 tarihinde https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines adresinden alındı.
80. Zeiger, H. (2021, March 29). Coronavirus vaccine ethics. The Center for Bioethics and Human Dignity. https://cbhd.org/content/coronavirus-vaccine-ethics